ProQR Names Boehringer Ingelheim CMO Dr. Lykke Hinsch Gylvin to Board
ProQR Therapeutics nominated Dr. Lykke Hinsch Gylvin—CMO and Head of Global Medicine at Boehringer Ingelheim with over 20 years leadership—to its Board of Directors. Her appointment, pending shareholder approval at the Annual General Meeting, aims to bolster expertise in drug development, oncology, immunology and rare diseases.
1. Board Nomination Details
ProQR Therapeutics has announced the nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors. The nomination is set to be voted on at the company’s upcoming Annual General Meeting, where shareholders will decide on her appointment as an independent non-executive director.
2. Dr. Gylvin’s Executive Background
Dr. Hinsch Gylvin currently serves as Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim, overseeing clinical development across oncology, cardiometabolic, immunology, CNS and rare diseases. She brings over 20 years of leadership experience from senior roles at Novartis, AstraZeneca, Roche, Novo Nordisk and Lundbeck.
3. Strategic Implications for ProQR
Her broad drug development expertise is expected to support ProQR’s Axiomer™ RNA editing platform and advance its pipeline of rare and prevalent disease therapies. The board addition underscores ProQR’s focus on strengthening global medical strategy and accelerating clinical progress.